// App-Quantinova.ai

1036 : CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Researchers

Presenter

  • Andrew Wei

Principal Investigators

  • Gail J. Roboz

  • Herv Dombret

  • Hartmut Dhner

  • Andre C. Schuh

  • Pau Montesinos

  • Christopher Pocock

  • Dominik Selleslag

  • Sergey N. Bondarenko

  • Ignazia La Torre

  • Barry Skikne

  • Keshava Kumar

  • Qian Dong

  • C.L. Beach

  • Farhad Ravandi

Medical Centers

  • Department of Clinical Haematology, Austin Hospital, Melbourne, Australia

  • Monash University, Australian Centre for Blood Diseases, Melbourne, Australia

  • Weill Medical College of Cornell University and the New York Presbyterian Hospital, New York, NY

  • Hopital Saint-Louis, Assistance Publique - Hopitaux De Paris (AP-HP), Paris, FRA

  • Institut de Recherche Saint-Louis, Université de Paris,Paris,France

  • University of Ulm, Ulm, Germany

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • CIBEROBN, Instituto de SaludCarlos III, Madrid, Spain

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Kent & Canterbury Hospital, Kent, United Kingdom

  • AZ Sint-Jan Brugge-Oostende, Brugge, Belgium

  • RM Gorbacheva Research Institute, Pavlov University,St Petersburg,Russia

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Kansas University Medical Center, Kansas City, KS

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • Australia

  • United States

  • France

  • Germany

  • Canada

  • Spain

  • United Kingdom

  • Belgium

  • Russia

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • CC-486

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved